Takeda May Resurrect IDM’s Bone Cancer Drug Mifamurtide In U.S.
Fate of IDM’s dendritic cell-based Uvidem and other cancer vaccines remains unclear after $75 million purchase.
Fate of IDM’s dendritic cell-based Uvidem and other cancer vaccines remains unclear after $75 million purchase.